Aqara Adds Presence Sensor FP2 to its Smart Sensor Portfolio
Aqara, a leading provider of smart home products, expands its wide-ranged smart sensor portfolio with the introduction of the Presence Sensor FP2, a revolutionary sensor for precise human presence detection. Equipped with the millimeter wave (mmWave) radar technology, the FP2 solves many pain points of the traditional passive infrared (PIR) presence sensors and enables a more tailored and rich smart home experience. The new sensor is now available on the Company’s Amazon brand stores in both North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK) as well as selective Aqara retailers worldwide1.
Accurate human presence detection provides essential information for tailored smart home automations such as home security monitoring and energy management systems (e.g., automated lights, HVAC, home appliances control). The mmWave-based FP2 Presence Sensor takes a leap forward from the PIR motion sensors as the former detects a person’s presence with even the slightest movement such as the act of breathing. Gone are the frustrating experiences of having your smart lights turn off unintentionally because you were sitting still reading a book or working at the desk.
Moreover, the FP2 sensor raises the precision of human detection to the next level with its capability to monitor multiple zones and multiple targets simultaneously. The FP2 allows the user to define up to 30 zones within a room (up to 40 sq m/430 sq ft). For example, the living room and dining area can be configured as separate zones with individualized automations. This sensor tracks up to 5 persons at the same time2, making it possible to control different zones based on the real-time location of each family member. For instance, to dim the dining area lights and switch the TV on when the kids leave the dining table and move to the sofa, meanwhile to keep the kitchen light on when someone is washing the dishes.
The powerful capabilities of the FP2 sensor can also be used within the third-party smart home platforms including Apple Home, Amazon Alexa, Google Home, Home Assistant3 and more. Once the zones are set up in the Aqara Home app, the zone configuration can be synced to these platforms as multiple motion/occupancy sensors, allowing users to trigger zone-based automation with a wide variety of third-party smart home devices. Support of the new smart home standard, Matter, is also planned for the FP2, and will be added to the device via a subsequent OTA update4.
Aside from its precise presence detection and multi-zone automations, FP2 also has fall detection built-in5, which is particularly essential for senior citizens who are more vulnerable to fall injuries. Families and caregivers can be alerted by both local siren and remote alerts if the FP2 sensor detects a fall, which allows them to seek immediate assistance if necessary. The FP2 sensor can detect a fall at the home in a convenient way without the need to wear additional devices on the body. At the same time, unlike a typical security camera, the Sensor provides meaningful alerts and data without intruding on a person’s personal privacy.
Thanks to its powerful hardware, the FP2 sensor will be able to support much more cutting-edge features in the future such as posture detection, which not only recognizes falls but also other postures including standing, sitting, and lying. Sleep monitoring and respiratory rate detection capabilities could also be achieved via the FP2 in the future. These advanced features will be added to the FP2 sensor via future OTA updates4.
For more details of the Presence Sensor FP2, please visit our website.
- Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real-time availability.
- The best result can be achieved in the case of tracking not more than 3 persons.
- The FP2 sensor can be added to Home Assistant using HomeKit Controller integration.
- Some features of the FP2 sensor such as Matter support, posture detection and sleep monitor are not available by the time of launch.
- The Presence Sensor FP2 is not a medical device, and can only be used for notification purposes. Ceiling-mounted installation is required for fall detection, and the monitoring area will decrease when the FP2 is ceiling-mounted. In fall detection mode, many functionalities of the FP2 become unavailable, including zone positioning and multi-person detection.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005024/en/
Contact information
For Media Inquiry:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
